Research
Hormonal
Lorcaserin produces modest but clinically meaningful weight loss (approx 3.2% more than placebo) with a favorable side effect profile compared to other agents, though long-term cardiovascular safety requires monitoring.
Lorcaserin (10mg, 2x daily) offers a moderate weight loss benefit (~3% more than placebo) with a generally well-tolerated side effect profile. It is a viable option for patients who cannot tolerate the side effects of other drugs or who need a modest boost to lifestyle changes. Long-term cardiovascular safety is still being monitored.
StrongQualifiesHIGH confidence
Lorcaserin decreased body weight modestly, by approximately 3.2 kg (≈3.2% of initial body weight) more than placebo. However, significantly more patients treated with lorcaserin 10 mg twice daily than placebo lost at least 5%... or at least 10%... of their initial weight.
Why this rating
Based on large randomized, placebo-controlled trials (BLOOM, BLOSSOM, BLOOM-DM) and meta-analysis.
Source
Long-term Drug Treatment for Obesity
Susan Z. Yanovski et al. · JAMA · 2013
DOI 10.1001/jama.2013.281361
Meta-analysis · 21 studiesCited 873×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-term use of FDA-approved obesity medications (orlistat, lorcaserin, phentermine/topiramate-ER) combined with lifestyle interventions produces statistically significant additional weight loss compared to placebo alone, with efficacy varying by drug class.Strong
- Phentermine plus topiramate-extended release (top dose) is the most effective FDA-approved obesity medication for long-term weight loss, producing approximately 9% weight loss relative to placebo at 1 year.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →